What’s Missing From Your PBM Evaluation

August 13, 2020

There’s ONE thing you aren’t evaluating your PBM on that you should be.

Evaluating pharmacy benefit managers (PBM) is never easy. Hidden costs, missing data and varying definitions can wreak havoc on the best of evaluations and skew PBM-to-PBM comparisons. It’s like comparing apples to oranges, the only thing they have in common is that they are fruit.

At the end of the day, plan sponsors want a PBM that not only delivers savings, but a partner they can trust to align with their goals. But, you won’t find either of those on a PBM evaluation scorecard.

However, a recent survey found that 35% of employers rated their PBMs as trustworthy and only 33% stated that their PBMs strongly align with their goals. Those are pretty jarring results. Obviously, trust and alignment are important to plan sponsors. It makes you think; why not consider a PBM’s value proposition during the initial evaluation?

Let’s dive deeper into this concept, starting with the basics.

What is a value proposition?

A value proposition refers to the value a company promises to deliver to customers should they choose to buy their product. The value proposition provides a declaration of intent or a statement that introduces a company’s brand to consumers by telling them what the company stands for, how it operates and why it deserves their business.

How are pbms evaluated?

The industry leans heavily on typical financial assessments throughout the evaluation process; especially in phase one. No standard method to financially asses PBMs exists, so it can get confusing quickly. Most consultants and plan sponsors focus on pricing factors that they are familiar with such as discounts, rebates, dispensing fees and administrative fees. This is commonly referred to as “spread sheeting.”

Where is the value proposition in all of this? Typically, taking time to evaluate the value prop is reserved for later in the process or at a finalist interview.

why does this matter?

Many PBMs are challenged to get past the “price point proposed metric assessment” and advance to a place in the evaluation process. Some PBMs want to be measured on actual performance expected and delivered once it has a client.

If the PBM doesn’t make it to a finalist interview, or to the next phase, then its value proposition is often lost. This is a disservice to the financial assessment, and ultimately the plan sponsor misses perhaps the strongest option for them – both financially and value-wise.

So, how can a consultant take a PBM’s value proposition and incorporate that into the intial evaluation? Good question. Our podcast guests tackled this issue head on in our latest episode— Creating a Win-Win for Consultants and Plan Sponsors.

Stay Informed and Connected

Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.

Navigating with a trusted partner

Now Available: 9th Annual Drug Trend Report

Our Drug Trend Report provides a clear view of the trends shaping pharmacy benefits today, along with strategies that are delivering real savings without compromising care.

Related blogs

Navigating Healthcare and Improving Outcomes

Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025

In this overview of our national Legal Ease webinar event, we highlight key federal and state developments shaping the conversation around PBM reform – and what they mean for your clients.  …

Navigating the Drug Supply Chain: What You Need to Know

Navigating the Drug Supply Chain: What You Need to Know

Before a prescription ever reaches a pharmacy counter, it has already moved through a complex ecosystem known as the drug supply chain. From manufacturers and wholesalers to pharmacy benefit managers (PBMs) and pharmacies, each entity plays a role in…

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars

Authors: Justin Arzt, PharmD; Agata Siwak, PharmD, MSBA; Marnie Wickizer, PharmD, AE-C, CDCES; Ryan Schmidt, PharmD; Robert Topp, RN, PhD; Matt Hustad, PharmD All authors are employees of Navitus Health Solutions. Abstract Adalimumab biosimilar adoption…

PBM 101: Why the Model Matters

PBM 101: Why the Model Matters

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are conduits of expertise, analytics and savings opportunities, poised to deliver exceptional health care while driving down costs. They coordinate between drug manufacturers,…

Associate Resource Group Spotlight: Green Team

Associate Resource Group Spotlight: Green Team

The Green Team believes that small changes lead to significant impact. Whether its reducing waste, conserving energy or implementing eco-friendly initiatives, they serve as an internal hub for expertise regarding environmental sustainability….

PBM 101: The Three PBM Business Models

PBM 101: The Three PBM Business Models

In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are regarded by the media as intermediaries between drug manufacturers, pharmacies, health plans and plan sponsors. But they’re so much more than that. PBMs act as conduits…

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)

This study examines the impact of implementing an automated point-of-sale diagnosis verification system for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to traditional utilization management approaches….

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings 

As the nation’s first 100% transparent, pass-through PBM, we continue to advance medication affordability by prioritizing upfront, real-time savings over rebated models….

Achieving Outstanding Results with Tailored Network Strategies

Achieving Outstanding Results with Tailored Network Strategies

A medium-sized city in Michigan with 1,350 members was seeking ways to lower its pharmacy benefit costs, which were growing under its existing traditional pharmacy benefit manager (PBM). With its member covered by a two-tier, open formulary including…

previous arrow
next arrow